LIVIVO - Search results -

Search results

Result 1 - 10 of total 129

Search options

Book ; Online: Hacia un estilo de nutrición saludable

Meneses Urrea, Luz Adriana / Uribe Ramírez, Juan David / Calderón Méndez, José Arnulfo / Álvarez Ramírez, Alba Aydee / López Peláez, Jéssica

2021

Keywords	Pharmacology ; Dislipidemias ; Lípidos ; Colesterol ; Grasas ; Metabolismo ; Hiperlipidemias ; Estrés ; Manejo del estrés ; Alimentación ; Actividad física y ejercicio ; Promoción de la salud ; Nutrición balanceada ; Estilo de vida ; Jóvenes
Language	0\|s
Size	1 electronic resource (91-113 pages)
Publisher	Universidad Santiago de Cali
Publishing place	Colombia
Document type	Book ; Online
Note	Spanish ; Open Access
HBZ-ID	HT021615534
ISBN	978-958-5147-69-0 ; 958-5147-69-6
Database	ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Book ; Online: Dislipidemias y estilos de vida de jóvenes

Álvarez Ramírez, Alba Aydee / López Peláez, Jéssica / Meneses Urrea, Luz Adriana / Díaz Velásquez, Diane María / Upegui Mayor, Anyi Tatiana / Arboleda Nava, Juliet Alejandra / Vásquez Mucúa, Angie Lisseth / Gordon Botero, Jennifer / Chinchilla Giraldo, Natalia / Uribe Ramírez, Juan David / Calderón Méndez, José Arnulfo / Dagua Gómez, Lina Marcela / Bautista Casadiego, Jean Paul / García Puerta, Melissa / Lectamo Caicedo, Lisbeth / Triviño Vargas, Geraldine Jimena / Prado Díaz, Alfredo / Gutiérrez Morales, Nataly / Mayor Sánchez, Yaneth

2021

Keywords	MMG ; Dislipidemias ; Lípidos ; Colesterol ; Grasas ; Metabolismo ; Hiperlipidemias ; Estrés ; Manejo del estrés ; Alimentación ; Actividad física y ejercicio ; Promoción de la salud ; Nutrición balanceada ; Estilo de vida ; Jóvenes
Language	0\|s
Size	1 electronic resource (1-182 pages)
Publisher	Universidad Santiago de Cali
Publishing place	Colombia
Document type	Book ; Online
Note	Spanish ; Open Access
HBZ-ID	HT021615533
ISBN	978-958-5147-69-0 ; 958-5147-69-6
Database	ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Rural treatment of COVID-19 patients with pirfenidone, nitazoxanide and colchicine. Case series.

Iturbe Esquivel, Brandon / Meneses Calderón, José / Concepción Carrillo, Luis Edgar / Mendieta Zeron, Hugo

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace

2022 Volume 93, Issue 1

Abstract: ... were included (mean age 44.5 ± 17.1 years), 12 women (mean age 45.9 ± 17.9 years) and 11 men (mean age ...

Abstract	Combined treatments against SARS-CoV-2 are emerging and some have taken into account the post-COVID-19 fibrosis. The aim of this survey was to report the experience of treating COVID-19 patients with pirfenidone, nitazoxanide (NTZ) and colchicine. It was a case series report of COVID-19 patients treated from December 2020 to March 2021, in a rural health center located in the State of Mexico, Mexico. 23 patients were included (mean age 44.5 ± 17.1 years), 12 women (mean age 45.9 ± 17.9 years) and 11 men (mean age 43 ± 16.9 years) with four deaths (17.39%). The evolution time was of 17.3 ± 6.7 days being the main symptoms fever (82.6%), myalgia (69.6%) and cough (65.2%). The main comorbidities were overweight/obesity 18 (78.26%), type 2 diabetes mellitus (T2DM) 4 (17.39%), Chronic obstructive pulmonary disease (COPD) 5 (21.73%) and systemic hypertension 2 (8.69%). Two patients were intubated and both died; in these cases, they refused to take NTZ until after three days the medical doctor had prescribed it for the first time. It can be concluded that implementing a mixed treatment with pirfenidone, NTZ and colchicine could improve the survival rate in ambulatory patients of low socioeconomic status.
MeSH term(s)	Male ; Humans ; Female ; Adult ; Middle Aged ; COVID-19 ; SARS-CoV-2 ; Diabetes Mellitus, Type 2 ; Colchicine/therapeutic use
Chemical Substances	nitazoxanide (SOA12P041N) ; pirfenidone (D7NLD2JX7U) ; Colchicine (SML2Y3J35T)
Language	English
Publishing date	2022-06-08
Publishing country	Italy
Document type	Journal Article
ZDB-ID	1160940-0
ISSN	1122-0643 ; 1120-0391
ISSN	1122-0643 ; 1120-0391
DOI	10.4081/monaldi.2022.2143
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 65: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Evolution of COVID-19 Pregnancies Treated With Nitazoxanide in a Third-Level Hospital.

Enríquez López, Krista Yazareth / Meneses Calderón, José / de la Cruz Ávila, Lilia / López Esquivel, Miguel Ángel / Meneses Figueroa, Jazmín / Vargas Contreras, María José / Anaya Herrera, José / Sotelo Martínez, Ofelia Roxana / Mendoza López, José Antonio / Mendieta Zerón, Hugo

Cureus

2021 Volume 13, Issue 5, Page(s) e15002

Abstract: Background Nitazoxanide shows ... ...

Abstract	Background Nitazoxanide shows adequate
Language	English
Publishing date	2021-05-13
Publishing country	United States
Document type	Journal Article
ZDB-ID	2747273-5
ISSN	2168-8184
ISSN	2168-8184
DOI	10.7759/cureus.15002
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Treatment with Hydroxychloroquine vs Hydroxychloroquine + Nitazoxanide in COVID-19 patients with risk factors for poor prognosis: A structured summary of a study protocol for a randomised controlled trial.

Calderón, José Meneses / Zerón, Hugo Mendieta / Padmanabhan, Srivatsan

Trials

2020 Volume 21, Issue 1, Page(s) 504

Abstract: Objectives: To determine the efficacy of Hydroxychloroquine vs. Hydroxychloroquine + Nitazoxanide in reducing the need for invasive mechanical ventilatory support for patients with COVID-19. Hydroxychloroquine is currently being used in multiple trials ... ...

Abstract	Objectives: To determine the efficacy of Hydroxychloroquine vs. Hydroxychloroquine + Nitazoxanide in reducing the need for invasive mechanical ventilatory support for patients with COVID-19. Hydroxychloroquine is currently being used in multiple trials with varying doses in an attempt to treat COVID-19. Nitazoxanide has powerful antiviral effects and proven efficacy against a range of viruses including SARS and MERS. Dual therapy by combining appropriate doses of these two medications with diverse activities against COVID-19 is expected to be better than monotherapy with hydroxychloroquine. Trial design: This is a single centre, randomized, controlled, single blinded, 2 arm (ratio 1:1) parallel group trial. Participants: 86 COVID-19 positive patients that are being treated at the Health Institute of the State of Mexico (ISEM) in Toluca, State of Mexico will be recruited from May 14 to December 31, 2020. Inclusion criteria: 1)Age older than 18 years.2)Hospitalised COVID-19 PCR test positive patients.3)Within the first 72 hours after performing the PCR test.4)Presence of risk factors for complications (at least one): over 60 years, history of diabetes mellitus, hypertension, and morbid obesity. Exclusion criteria: 1)Patients with corrected QT interval (QTc) greater than 500ms at hospital admission.2)Patients who have inherent contraindications to each drug.3)Patients who are unable to consent.4)Patients who have previously received chloroquine.5)Patients already intubated. Elimination criteria: 1)Patients whose clinical follow-up is lost or who decide not to continue in the study INTERVENTION AND COMPARATOR: The two management alternatives will be: Control - Hydroxychloroquine 200 mg taken orally every 12 hours for 7 days. Dual therapy - Hydroxychloroquine 400 mg taken orally every 12 hours for two days and then 200 mg taken orally every 12 hours for four days + Nitazoxanide 500 mg orally every 6 hours taken with food, for seven days. Main outcomes: Primary: Mechanical ventilation requirement assessed at one week. Percentage of COVID-19 positive patients who require mechanical ventilation . All patients will be monitored till hospital discharge or death. Randomisation: Patients will be randomly allocated using allocation papers and opaque sealed envelopes to either receive the placebo or the dual therapy intervention treatment in a 1:1 ratio until we have recruited the required number of patients for each group. Blinding (masking): Trial participants will be blinded. Numbers to be randomised (sample size): 86 participants will be randomized to each group, with 43 in the control group and 43 in the dual therapy group. Trial status: Protocol version: 2, recruitment will begin on May 14 until sample size is reached , with the analysis deadline of December 31st 2020. Trial registration: ClinicalTrials.gov Identifier: NCT04341493. Date of trial registration: April 10, 2020 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
MeSH term(s)	Betacoronavirus ; COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/drug therapy ; Drug Therapy, Combination ; Humans ; Hydroxychloroquine/administration & dosage ; Hydroxychloroquine/therapeutic use ; Nitro Compounds ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/drug therapy ; Prognosis ; Randomized Controlled Trials as Topic ; Respiration, Artificial ; Risk Factors ; SARS-CoV-2 ; Single-Blind Method ; Thiazoles/administration & dosage
Chemical Substances	Nitro Compounds ; Thiazoles ; Hydroxychloroquine (4QWG6N8QKH) ; nitazoxanide (SOA12P041N)
Keywords	covid19
Language	English
Publishing date	2020-06-08
Publishing country	England
Document type	Clinical Trial Protocol ; Letter
ZDB-ID	2040523-6
ISSN	1745-6215 ; 1468-6694 ; 1745-6215
ISSN (online)	1745-6215
ISSN	1468-6694 ; 1745-6215
DOI	10.1186/s13063-020-04448-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Rural treatment of COVID-19 patients with pirfenidone, nitazoxanide and colchicine. Case series

Brandon Iturbe Esquivel / José Meneses Calderón / Luis Edgar Concepción Carrillo / Hugo Mendieta Zeron

Monaldi Archives for Chest Disease (2022)

2022

Abstract: ... were included (mean age 44.5 ± 17.1 years), 12 women (mean age 45.9 ± 17.9 years) and 11 men (mean age ...

Abstract	Combined treatments against SARS-CoV-2 are emerging and some have taken into account the post-COVID-19 fibrosis. The aim of this survey was to report the experience of treating COVID-19 patients with pirfenidone, nitazoxanide (NTZ) and colchicine. It was a case series report of COVID-19 patients treated from December 2020 to March 2021, in a rural health center located in the State of Mexico, Mexico. 23 patients were included (mean age 44.5 ± 17.1 years), 12 women (mean age 45.9 ± 17.9 years) and 11 men (mean age 43 ± 16.9 years) with four deaths (17.39%). The evolution time was of 17.3 ± 6.7 days being the main symptoms fever (82.6%), myalgia (69.6%) and cough (65.2%). The main comorbidities were overweight/obesity 18 (78.26%), type 2 diabetes mellitus (T2DM) 4 (17.39%), Chronic obstructive pulmonary disease (COPD) 5 (21.73%) and systemic hypertension 2 (8.69%). Two patients were intubated and both died; in these cases, they refused to take NTZ until after three days the medical doctor had prescribed it for the first time. It can be concluded that implementing a mixed treatment with pirfenidone, NTZ and colchicine could improve the survival rate in ambulatory patients of low socioeconomic status.
Keywords	colchicine ; COVID-19 ; nitazoxanide ; pirfenidone ; pulmonary fibrosis ; Medicine ; R
Subject code	616
Language	English
Publishing date	2022-06-01T00:00:00Z
Publisher	PAGEPress Publications
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Treatment with Hydroxychloroquine vs Hydroxychloroquine + Nitazoxanide in COVID-19 patients with risk factors for poor prognosis

José Meneses Calderón / Hugo Mendieta Zerón / Srivatsan Padmanabhan

Trials, Vol 21, Iss 1, Pp 1-

A structured summary of a study protocol for a randomised controlled trial

2020 Volume 3

Abstract: Abstract Objectives To determine the efficacy of Hydroxychloroquine vs. Hydroxychloroquine + Nitazoxanide in reducing the need for invasive mechanical ventilatory support for patients with COVID-19. Hydroxychloroquine is currently being used in multiple ... ...

Abstract	Abstract Objectives To determine the efficacy of Hydroxychloroquine vs. Hydroxychloroquine + Nitazoxanide in reducing the need for invasive mechanical ventilatory support for patients with COVID-19. Hydroxychloroquine is currently being used in multiple trials with varying doses in an attempt to treat COVID-19. Nitazoxanide has powerful antiviral effects and proven efficacy against a range of viruses including SARS and MERS. Dual therapy by combining appropriate doses of these two medications with diverse activities against COVID-19 is expected to be better than monotherapy with hydroxychloroquine. Trial design This is a single centre, randomized, controlled, single blinded, 2 arm (ratio 1:1) parallel group trial. Participants 86 COVID-19 positive patients that are being treated at the Health Institute of the State of Mexico (ISEM) in Toluca, State of Mexico will be recruited from May 14 to December 31, 2020. Inclusion criteria: 1) Age older than 18 years. 2) Hospitalised COVID-19 PCR test positive patients. 3) Within the first 72 hours after performing the PCR test. 4) Presence of risk factors for complications (at least one): over 60 years, history of diabetes mellitus, hypertension, and morbid obesity. Exclusion criteria: 1) Patients with corrected QT interval (QTc) greater than 500ms at hospital admission. 2) Patients who have inherent contraindications to each drug. 3) Patients who are unable to consent. 4) Patients who have previously received chloroquine. 5) Patients already intubated. Elimination criteria: 1) Patients whose clinical follow-up is lost or who decide not to continue in the study Intervention and comparator The two management alternatives will be: Control - Hydroxychloroquine 200 mg taken orally every 12 hours for 7 days. Dual therapy - Hydroxychloroquine 400 mg taken orally every 12 hours for two days and then 200 mg taken orally every 12 hours for four days + Nitazoxanide 500 mg orally every 6 hours taken with food, for seven days. Main outcomes Primary: Mechanical ventilation requirement assessed at one week. Percentage of COVID-19 positive patients who require mechanical ventilation . All patients will be monitored till hospital discharge or death. Randomisation Patients will be randomly allocated using allocation papers and opaque sealed envelopes to either receive the placebo or the dual therapy intervention treatment in a 1:1 ratio until we have recruited the required number of patients for each group. Blinding (masking) Trial participants will be blinded. Numbers to be randomised (sample size) 86 participants will be randomized to each group, with 43 in the control group and 43 in the dual therapy group. Trial Status Protocol version: 2, recruitment will begin on May 14 until sample size is reached , with the analysis deadline of December 31st 2020. Trial registration ClinicalTrials.gov Identifier: NCT04341493. Date of trial registration: April 10, 2020 Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol
Keywords	COVID-19 ; Randomised controlled trial ; protocol ; Dual therapy ; hydroxychloroquine ; nitazoxanide ; Medicine (General) ; R5-920 ; covid19
Subject code	610
Language	English
Publishing date	2020-06-01T00:00:00Z
Publisher	BMC
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Adaptive changes in redox response and decreased platelet aggregation in lead-exposed workers.

Hernández-García, Sandra / Flores-García, Mirthala / Maldonado-Vega, María / Hernández, Gerardo / Meneses-Melo, Facundo / López-Vanegas, Nadia-Cristina / Calderón-Salinas, José-Víctor

Environmental toxicology and pharmacology

2023 Volume 100, Page(s) 104134

Abstract: Chronic lead exposure can generate pro-oxidative and pro-inflammatory conditions in the blood, related to high platelet activation and aggregation, altering cell functions. We studied ADP-stimulated aggregation and the oxidant/antioxidant system of ... ...

Abstract	Chronic lead exposure can generate pro-oxidative and pro-inflammatory conditions in the blood, related to high platelet activation and aggregation, altering cell functions. We studied ADP-stimulated aggregation and the oxidant/antioxidant system of platelets from chronically lead-exposed workers and non-exposed workers. Platelet aggregation was low in lead-exposed workers (62 vs. 97%), who had normal platelet counts and showed no clinical manifestations of hemostatic failure. ADP-activated platelets from lead-exposed workers failed to increase superoxide release (3.3 vs. 6.6 µmol/g protein), had low NADPH concentration (60 vs. 92 nmol/mg protein), high concentration of hydrogen peroxide (224 vs. 129 nmol/mg protein) and high plasma PGE
MeSH term(s)	Humans ; Platelet Aggregation ; Lead/toxicity ; Blood Platelets ; Reactive Oxygen Species/metabolism ; Oxidation-Reduction ; Adenosine Diphosphate/metabolism
Chemical Substances	Lead (2P299V784P) ; Reactive Oxygen Species ; Adenosine Diphosphate (61D2G4IYVH)
Language	English
Publishing date	2023-04-26
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	1318302-3
ISSN	1872-7077 ; 1382-6689
ISSN (online)	1872-7077
ISSN	1382-6689
DOI	10.1016/j.etap.2023.104134
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4490: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Treatment with Hydroxychloroquine vs Hydroxychloroquine + Nitazoxanide in COVID-19 patients with risk factors for poor prognosis

Meneses Calderón, José / Mendieta Zerón, Hugo / Padmanabhan, Srivatsan

A structured summary of a study protocol for a randomised controlled trial.

2020

Abstract	Objectives: To determine the efficacy of Hydroxychloroquine vs. Hydroxychloroquine + Nitazoxanide in reducing the need for invasive mechanical ventilatory support for patients with COVID-19. Hydroxychloroquine is currently being used in multiple trials with varying doses in an attempt to treat COVID-19. Nitazoxanide has powerful antiviral effects and proven efficacy against a range of viruses including SARS and MERS. Dual therapy by combining appropriate doses of these two medications with diverse activities against COVID-19 is expected to be better than monotherapy with hydroxychloroquine. Trial design: This is a single centre, randomized, controlled, single blinded, 2 arm (ratio 1:1) parallel group trial.
Keywords	Hydroxychloroquine ; Nitazoxanide ; COVID-19 ; Risk factors ; MEDICINA Y CIENCIAS DE LA SALUD ; covid19
Language	English
Publisher	Trials
Publishing country	mx
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Period prevalence and anthropometric predictors of premature rupture of membranes in Mexican women, 2009-2012.

Hernández-Garduño, Eduardo / Meneses-Calderón, José

Salud publica de Mexico

2017 Volume 59, Issue 2, Page(s) 122–123

MeSH term(s)	Adolescent ; Adult ; Body Height ; Body Weight ; Case-Control Studies ; Female ; Fetal Membranes, Premature Rupture/epidemiology ; Humans ; Mexico ; Pregnancy ; Prevalence ; Time Factors ; Young Adult
Language	English
Publishing date	2017-05-31
Publishing country	Mexico
Document type	Letter
ZDB-ID	954220-6
ISSN	1606-7916 ; 0036-3634
ISSN (online)	1606-7916
ISSN	0036-3634
DOI	10.21149/8230
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 1309: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito